Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.

Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.

6 reports, 2 independent Updated Wed 00:00
No new developments lately
Reports
6
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Hyperion trial data provided for Merck drug, leading to FDA label update.1 source
  2. FDA granted priority review for Merck's drug application based on ZENITH trial data.
  3. Merck submitted Winrevair for FDA approval, supported by ZENITH, HYPERION, and Stellar study data.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story